Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model [0.03%]
奥氏木单抗皮下注射治疗复发性多发性硬化症的预算影响模型分析
Camilla Porta,Paolo Di Procolo,Giuseppina Marrazzo et al.
Camilla Porta et al.
Objectives: The aim of this study was to evaluate the budget impact of introducing the subcutaneous (SC) form of ocrelizumab for patients with relapsing forms of multiple sclerosis (RMS) with high disease activity (HA) de...
Correction: Retractions of Health Economic Evaluations: A Systematic Review [0.03%]
纠正：卫生经济评估的撤回：一项系统综述
Eric Julian Manalastas,Aditi Hombali,Juliette C Thompson et al.
Eric Julian Manalastas et al.
Published Erratum
PharmacoEconomics - open. 2026 Jul 31. DOI:10.1007/s41669-026-00671-w 2026
AMPLIFY: Estimating Clinical and Humanistic Benefits of Pembrolizumab in Portugal [0.03%]
通过AMPLIFY估算帕博利珠单抗在葡萄牙的临床和人文化效益
Pedro Cardoso,Joana Sousa,João Ferreira et al.
Pedro Cardoso et al.
Background: Pembrolizumab has become a cornerstone in the treatment of multiple tumor types. In Portugal, it is currently reimbursed across 25 indications. However, a comprehensive holistic assessment of its cumulative cl...
Economic Impact of PromarkerD In Vitro Diagnostic Testing on the Management of Chronic Kidney Disease in Type 2 Diabetes: A Budget Impact Analysis [0.03%]
PromarkerD体外诊断检测对2型糖尿病慢性肾脏病管理的经济影响：预算影响分析
Gareth C Fernandez,Isabella A Joubert,Kirsten E Peters et al.
Gareth C Fernandez et al.
Objectives: This study evaluated the clinical and economic impact of integrating Promarker®D, a validated biomarker-based blood test that predicts kidney function decline up to 4 years before clinical evidence of chronic...
A Scoping Review of Methods for Extrapolating Costs and Effects in Economic Evaluations of Remote Monitoring [0.03%]
远程监测卫生技术经济评价的成本和效果外推方法的系统评价研究
Sabine Michelsen Raunbak,Jakob Juul Christensen,Ulla Møller Weinreich et al.
Sabine Michelsen Raunbak et al.
Introduction: Telehealth, including remote monitoring, has the potential to reduce healthcare resource use. However, economic evaluations often have insufficient methodological quality, including long-term investigation. ...
Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain [0.03%]
特泽佩卢玛布与奥马利珠单抗治疗西班牙重度不受控制的过敏性哮喘患者的成本效益分析
Elena Villamañan,Santiago Quirce,Covadonga Torres et al.
Elena Villamañan et al.
Background: Severe uncontrolled asthma (SUA) represents a complex and heterogeneous form of asthma that persists despite treatment. Allergic immunoglobulin E (IgE)-mediated SUA can be treated with tezepelumab or omalizuma...
Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China [0.03%]
中国安徽省免疫检查点抑制剂的可及性、价格和患者支付能力：横断面研究
Tongming Zhu,Kunkun Ge,Aizong Shen et al.
Tongming Zhu et al.
Background/aim: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet their uptake in low- and middle-income areas is hindered by high prices and uneven distribution. Anhui Province, China-characteri...
Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model [0.03%]
采用动态传播模型估计全葡萄牙普及水痘疫苗的长期临床和经济影响
Colleen Burgess,Stephanie A Kujawski,Miguel Amorim et al.
Colleen Burgess et al.
Background: Varicella vaccination is not currently included in Portugal's childhood national immunization program. We modeled the clinical and economic impact of a two-dose universal varicella vaccination (UVV) program in...
A Targeted Review of Available Data Sources to Support Evidence-Informed Decisions: Implications for Health Technology Assessment in South Africa [0.03%]
可用数据来源支持循证决策的专题回顾：对南非卫生技术评估的意义
Evelyn Thsehla,Celeste Holden,Micheal Boachie et al.
Evelyn Thsehla et al.
Background: Universal health coverage (UHC) is central to the global health agenda. South Africa is in the process of developing a single financing system for UHC through a National Health Insurance (NHI). The NHI Act leg...
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer [0.03%]
结构化专家咨询与外部证据相结合，助力提早进行报销决策：Selpercatinib治疗非小细胞肺癌的挪威案例研究
Yancy S Wu,Emily A Burger,Fredrik Holmboe et al.
Yancy S Wu et al.
Background: The Norwegian public-private partnership, CONNECT, identified the reimbursement submission case of selpercatinib-a first-line targeted therapy for RET fusion-positive non-small cell lung cancer (NSCLC)-as a un...